Unknown PHASE3 INTERVENTIONAL 2-arm NCT04163237

Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

Study on Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

Sponsor: Guangxi Medical University

Updated 5 times since 2019 Last updated: Nov 13, 2019 Started: Dec 1, 2019 Primary completion: Oct 31, 2020 Completion: Nov 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04163237, this PHASE3 trial focuses on Advanced Liver Cancer and remains ongoing. Sponsored by Guangxi Medical University, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE3
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangxi Medical University

Data source: Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China